Home > Insider Trading > Filing (0001209191-23-007917)

Filing Details

Accession Number:: 0001209191-23-007917
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-02-08 19:56:31
Reporting Period:: 2023-02-06

Accepted Time:: 2023-02-08 19:56:31
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
914475	Neurocrine Biosciences Inc	NBIX	Biological Products, (No Disgnostic Substances) (2836)	330525145

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1776977	Julie Cooke	12780 El Camino Real San Diego CA 92130	Chief Human Resources Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2023-02-06	640	$105.47	16,501	No	4	S	Direct
Common Stock	Disposition	2023-02-06	575	$104.28	15,926	No	4	S	Direct
Common Stock	Disposition	2023-02-07	913	$102.25	16,749	No	4	S	Direct
Common Stock	Disposition	2023-02-07	12,801	$102.41	28,246	No	4	S	Direct
Common Stock	Disposition	2023-02-07	822	$104.03	27,424	No	4	S	Direct
Common Stock	Disposition	2023-02-08	700	$103.95	28,052	No	4	S	Direct
Common Stock	Disposition	2023-02-08	628	$103.69	27,424	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Sale of 640 shares of common stock issued upon vesting of 1,215 restricted stock units on February 6, 2022 to cover payroll and withholding taxes, with the balance of the shares (575) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.05 to $106.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Sale of 913 shares of common stock issued upon vesting of 1,736 restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (823) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.87 to $103.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Sale of 12,801 shares of common stock issued upon vesting of 24,298 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (11,497) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan
The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.03 to $103.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Sale of 700 shares of common stock issued upon vesting of 1,328 restricted stock units on February 8, 2022 to cover payroll and withholding taxes, with the balance of the shares (628) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.58 to $105.72. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.